Cannabis use and hyperemesis gravidarum: clinical approach

Introduction and clinical context

The study Cannabis use and hyperemesis gravidarum: clinical approach (PubMed · 2023) is part of the scientific research on the use of cannabinoids in pregnancy.

This section is a warning. The available evidence associates cannabis use in pregnancy with adverse neonatal outcomes — such as preterm birth and low birth weight — and with possible impacts on fetal and child development. For this reason, guidelines advise against cannabis use during pregnancy and breastfeeding. There is also attention to cannabinoid hyperemesis syndrome. Pregnant women should always talk to their doctor before any use.

Understanding what science shows about the use of cannabinoids in pregnancy helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This study evaluated the topic based on clinical data. Attention to cannabinoid hyperemesis syndrome (paradoxical effect); guidance against use in pregnancy. The findings contribute to the body of evidence and should be interpreted in the context of other studies. Each study adds to the body of evidence guiding the responsible use of cannabinoids.

Mechanism of action and safety

This section is a safety warning. THC crosses the placenta and is excreted in breast milk, and prenatal exposure to cannabinoids has been associated with adverse outcomes and possible impacts on neurodevelopment. For this reason, guidelines advise against cannabis use in pregnancy and breastfeeding. There is also the risk of cannabinoid hyperemesis syndrome, a paradoxical picture of intense vomiting. Given the uncertainties and potential harms, the recommendation is maximum caution: no pregnant woman should use cannabis without explicit medical guidance.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (PubMed · 2023). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Can I use cannabis in pregnancy?

Guidelines advise against it: there is an association with adverse outcomes. Always talk to your doctor.

What is cannabinoid hyperemesis?

A paradoxical picture of intense vomiting linked to cannabis use, relevant in pregnancy.

---

About this content

This page is a summary of scientific research published by third parties, provided for informational and educational purposes. Brazcann did not conduct, fund or sponsor the studies summarised here, and does not manufacture, sell, distribute or supply cannabis products.

This content is not a recommendation, therapeutic indication, prescription or medical advice, and does not replace assessment by a qualified professional. Study results do not guarantee individual efficacy, and publication of a study does not mean regulatory approval in Brazil.

Please consult the primary source cited on this page.

Last reviewed: 30/07/2026